Increased PYCR1 mRNA predicts poor prognosis in kidney adenocarcinoma
A study based on TCGA database

Tianyi Zhang, MMa, Ying Liu, MMb, Wenyi Liu, MMc, Junwu Mei, MMb, Ying Huang, MMb, Pan Lv, MMb, Lu Meng, MMb, Yinhua Li, MMb, Yunge Jia, MMb, Xuezheng Liu, PhDb,c, Zhongfu Zuo, PhDb,c,d,∗

Abstract
The pyrroline-5-carboxylate reductase 1 (PYCR1) plays important roles in cancers, but its contribution to adenocarcinoma of the kidney (AK) and the potential mechanism remain to be clarified. In this study, we aimed to demonstrate the relationship between PYCR1 mRNA and AK based on The Cancer Genome Atlas database.

PYCR1 mRNA in AK and normal tissues was compared using Wilcoxon rank sum test. The relationship between PYCR1 mRNA and clinicopathological characters was evaluated using logistic regression. The association between PYCR1 mRNA and survival rate was evaluated using Kaplan-Meier test and Cox regression of univariate and multivariate analysis. Additionally, Gene Set Enrichment Analysis was conducted to annotate the biological function of PYCR1 mRNA.

Increased PYCR1 mRNA was found in AK tissues. Increased PYCR1 mRNA was related to high histologic grade, clinical stage, and lymph node and distant metastasis. Kaplan-Meier survival analysis and univariate analysis showed that AK patients with increased PYCR1 mRNA had worse prognosis than those without. PYCR1 mRNA remained independently associated with overall survival (HR: 1.34; 95% CI: 1.07–1.66; P = .009) in multivariate analysis. The Gene Set Enrichment Analysis suggested that ribosome, proteasome, inhibition of p53 signaling pathway, extracellular matrix receptor interaction, and homologous recombination were differentially enriched in increased PYCR1 mRNA phenotype.

Increased PYCR1 mRNA is a potential marker in patients with AK. More importantly, p53 pathway, ribosome, proteasome, extracellular matrix receptor interaction, and homologous are differentially enriched in AK patients with increased PYCR1 mRNA.

Abbreviations: AK = adenocarcinoma of the kidney, GSEA = Gene Set Enrichment Analysis, PYCR1 = pyrroline-5-carboxylate reductase 1, TCGA = The Cancer Genome Atlas.

Keywords: adenocarcinoma, GSEA, kidney prognosis, PYCR1, TCGA

1. Introduction
Adenocarcinoma of the kidney (AK), also known as renal cell carcinoma, mostly originates from renal tubular epithelial cells. AK is one of the most common malignant tumors of urinary system, and is the ninth most common malignant tumor in Western countries with about 403,000 new cases and 175,000 deaths worldwide reported every year.1 The incidence of AK has been steadily increasing by 2% to 4% each year and the mortality rate has also been increasing.2 AK is insensitive to traditional radiotherapy and chemotherapy, which only improves a survival rate of less than 10% in 5 years after disease metastasis.3 Currently, surgical resection is the most effective treatment for
early-stage AK. Most patients have AK cancer of stage I and have the best prognosis, whereas AK patients of stage III and stage IV have worse prognosis.\[4\] Additionally, there are no effective biomarkers for prognosis and for direct treatment (adjunct radiation and/or chemotherapy) of AK. Therefore, novel approaches for diagnosis, treatment, and prognosis of AK are needed.

Proline is a unique and non-essential amino acid in humans, which has been recognized as a structural disruptor and indicator of various pathological stresses during tumorigenesis.\[5,6\] The metabolism and synthesis of proline are involved in tricarboxylic acid cycle, urea cycle, and pentose phosphate pathway.\[7,8\] Proline also plays key roles in cellular signaling processes, cellular bioenergetics, and cancer cell metabolism.\[9–11\] Dehydrogenase/oxidase is the first enzyme of proline catabolism, and pyrrole-5-carboxylate reductase (PYCR) is the final key enzyme that catalyzes the synthesis of proline, including PYCR1, PYCR2, and PYCR like.\[12\] It has been demonstrated that PYCR1 may play an important role in tumorigenesis.\[13–15\] PYCR1 is overexpressed in breast cancer, prostate cancer, and lung cancer cells, whereas silencing PYCR1 suppresses tumor cell proliferation and survival.\[13,15\] Recent studies indicate broad effects of proline metabolism on cancer cell growth and survival, which suggests that proline metabolic enzymes can serve as potential targets for therapeutic intervention.\[13,15–17\] However, the correlation between PYCR1 and the prognosis of AK has not been reported.

In this study, we explored the potential relations between PYCR1 mRNA and AK using the data from The Cancer Genome Atlas (TCGA) database. The relationship of PYCR1 with prognosis of AK was evaluated. The PYCR1-related biological pathways that involved in AK pathogenesis were analyzed. Our findings demonstrate that the increased PYCR1 mRNA may be associated with poor survival of AK.

### 2. Material and methods

The study is systematic review, so ethical approval and patient consent are not needed.

#### 2.1. Bioinformatics analysis

The gene expression data (941 cases, Workflow Type: HTSeq-FPKM) and corresponding clinical information were downloaded from TCGA database (https://portal.gdc.cancer.gov). Boxplots were used to visualize differential expressions between discrete variables.\[13\] The RNA-Seq data and clinic data of 539 patients with AK were used for further analysis.

#### 2.2. Gene set enrichment analysis

A list of genes according to their correlation with PYCR1 mRNA was generated using Gene Set Enrichment Analysis (GSEA).\[14\] The mRNA level of PYCR1 was used as a phenotype label. The nominal $P$ value and normalized enrichment score were used to sort the pathways enriched in each phenotype.

#### 2.3. Statistical analysis

All statistical analyses were conducted using R package (v.3.6.1). The relationship between clinical pathologic features and PYCR1 mRNA was analyzed using the Wilcoxon signed-rank test and logistic regression. The relationship between clinopathologic characteristics associated with overall survival of patients was analyzed using Cox regression of univariate analysis and the Kaplan-Meier methods. Multivariate Cox analysis was used to compare the effect of PYCR1 mRNA on survival as well as other clinical characteristics (stage, grade, histology, myometrial invasion, lymph node metastasis, and distant metastasis). The cutoff value of PYCR1 mRNA was determined by its median value. $P < .05$ was considered as statistically significant.

### 3. Results

#### 3.1. Clinopathologic characteristics of AK patients from TCGA

The clinical data and gene expression data in 941 patients with primary AK tumors were downloaded from TCGA in January 2020 and shown in Table 1. Their median age was 54 (range 17–90) years old. For histologic grade, 14 (2.5%) cases were well differentiated AK tumors, 230 (43.6%) were with moderately differentiated, and 282 (53.9%) were with poorly differentiated. For tumor status, 72 patients were of tumor-free (11.9%) and 539 were with tumors (88.1%). For tumor clinical TNM stage, 265 patients were with stage I tumor (50.4%), 54 were with stage II (10.3%), 124 were with stage III (23.6%), and 83 were with stage IV (15.7%). Additionally, 51 (13.1%) cases had lymph node metastases (pelvic and para-aortic), and 90 (14.0%) cases had distant metastases. The median follow-up time for subjects alive at last contact was 30.7 months (range 0–198 months).

#### 3.2. Association between PYCR1 mRNA and clinopathologic characteristics

A total of 941 AK samples from TCGA with PYCR1 mRNA expression were analyzed. As shown in Figure 1A and B, PYCR1 mRNA was increased in tumor samples, and correlated significantly with clinical TNM stage ($P < .001$) (Fig. 1C).
cutoff value of PYCR1 mRNA expression, which was determined based on the median value, was 2.2. Univariate analysis using logistic regression revealed that, as a categorical dependent variable, PYCR1 mRNA was associated with poor prognostic clinicopathologic characteristics (Table 2). In detail, increased PYCR1 mRNA in AK was significantly associated with high histologic grade (OR = 2.8 for well, moderate vs poor), clinical stage (OR = 4.0 for IV vs I), and distant metastasis (OR = 3.0 for positive vs negative) (P < .05). These results suggest that AK with increased PYCR1 mRNA is prone to progress to a more advanced stage than those without.

3.3. Survival analysis

Based on the cutoff value of PYCR1, the patients were grouped into those with increased PYCR1 expression (n = 539) and those without (n = 72). Kaplan-Meier survival analysis showed that AK patients with increased PYCR1 mRNA had a worse prognosis than those without (Fig. 2A, P < .001). The univariate analysis revealed that increased PYCR1 mRNA correlated with a poor overall survival significantly (HR: 1.05, 95% CI: 1.03–1.07; P < .001) (Table 3). Other clinicopathologic variables associated with poor survival included advanced stage, positive lymph nodes, distant metastasis, and deep myometrial invasion (Table 3). Multivariate analysis showed that PYCR1 mRNA remained significant association with overall survival independently (HR: 1.36, 95% CI: 1.08–1.66; P = .009) (Fig. 2B).

3.4. GSEA identifies PYCR1-related signaling pathways

To identify signaling pathways that are differentially activated in AK, we conducted GSEA analysis between data sets with decreased and increased PYCR1 mRNA. The enrichment plots from GSEA were shown in Figure 3, in which each curve represents a pathway. GSEA revealed significant differences in the enrichment of MSigDB Collection (c2.cp.kegg.v6.2.symbols.gmt) between the 2 datasets (FDR q < 0.25, NOM P value < .05). We selected the most significantly enriched signaling pathways based on their normalized enrichment score and showed them in Table 4 and Figure 3. Ribosome, proteasome, p53 pathway, ECM receptor interaction, and homologous recombination were differentially enriched in elevated PYCR1 mRNA phenotype (Table 4 and Fig. 3).

4. Discussion

As a member of PYCR, PYCR1 is highlighted in the biosynthesis of proline in various tumors. For instance, PYCR1 cooperates with isocitrate dehydrogenase 1 to promote cancer cell survival in glioma and esophageal squamous cell cancer. PYCR1 is screened out in 19 cancers and proposed as a novel enzyme. PYCR1 is overexpressed in several cancer tissues, suggesting that it may be closely related to the development and progression of cancer. However, the expression and related functions of PYCR1 in AK are still unclear.

In this study, we collected high throughput RNA sequencing data of AK from TCGA database and demonstrated that PYCR1 mRNA was significantly up-regulated in AK tissues compared with normal kidney tissue or adjacent normal tissues of kidney cancer. Moreover, increased PYCR1 mRNA in AK was positively correlated with high clinical stage and poor prognosis. Univariate and multivariate Cox analyses indicated that the PYCR1 mRNA may be a useful biomarker for AK prognosis. Furthermore, we investigated the function of PYCR1 in kidney cancer tissues using GSEA, and showed that the p53 pathway, ribosome, proteasome, the ECM receptor interaction, and homologous recombination were found differentially and significantly enriched in increased PYCR1 mRNA phenotype. These pathways, especially the p53 pathway, are reported to contribute to cancer cell proliferation, invasion, and metastasis. This implies the potential role of PYCR1 as a prognostic target in AK. A recent study reported that a fraction of kindlin-2 localized to mitochondria and interacted with PYCR1. ECM stiffening promoted kindlin-2 translocation into mitochondria, resulted in elevation of PYCR1 expression and thus increased proline synthesis and cell proliferation. Depletion of kindlin-2 reduced PYCR1 level, increased reactive oxygen species...
Figure 2. Survival analysis. (A) Association between PYCR1 mRNA and survival rate (n = 539). (B) Hazard ratio with multivariate survival model (n = 246). PYCR1 = pyrroline-5-carboxylate reductase 1.

Table 3

Association between overall survival and clinicopathologic characteristics of patients.

| Clinical characteristics                      | HR (95% CI)          | P value |
|-----------------------------------------------|----------------------|---------|
| a                                             |                      |         |
| Age (continuous)                              | 1.02 (1.00–1.04)     | .012    |
| PYCR1 expression (high vs low)                | 1.05 (1.03–1.07)     | .000    |
| Grade (well or moderate vs poor)              | 2.24 (1.68–2.99)     | .000    |
| Stage (IV vs I)                               | 1.86 (1.54–2.25)     | .000    |
| Distant metastasis (positive vs negative)     | 1.94 (1.53–2.46)     | .000    |
| Lymph nodes (positive vs negative)            | 2.93 (1.51–5.67)     | .000    |
| b                                             |                      |         |
| PYCR1 expression (high vs low)                | 1.36 (1.08–1.66)     | .009    |
| Myometrial invasion (≥50% vs <50%)            | 1.71 (0.76–3.84)     | .194    |
| Age (continuous)                              | 1.03 (1.01–1.05)     | .002    |

a: Categorical dependent variable, greater or less than the median expression level.
b: Multivariate survival model after variable selection.
PYCR1 = pyrrolidine-5-carboxylate reductase 1.

Figure 3. Enrichment plots from Gene Set Enrichment Analysis (GSEA). Ribosome (A), p53 signaling pathway (B), homologous recombination (C), extracellular matrix receptor interaction (D), proteasome (E), and ALS (F) were differentially enriched in PYCR1-related AK, adenocarcinoma of the kidney. (G) Enrichment plots from gene set enrichment analysis (GSEA). Each curve represents a pathway. ES = enrichment score, NES = normalized enrichment score, NOM p-val = normalized P value, PYCR1 = pyrroline-5-carboxylate reductase 1.
production and apoptosis, and abolished ECM stiffening-induced proline synthesis and cell proliferation. A mecanoresponsive kindlin-2-PYCR1 complex that linked mechano-environment to proline metabolism and signaling was also revealed, suggesting its potential to inhibit tumor growth. Moreover, PYCR1 promotes ECM adhesion, actin cytoskeletal contraction, cell survival, proliferation, metabolic reprogramming, and collagen matrix deposition in both lung adenocarcinoma cells and associated fibroblasts, which collectively contribute to the progression of lung adenocarcinoma.

Our results also indicate that PYCR1 mRNA alterations may be associated with ribosome, proteasome and p53 signaling pathway in AK. The ribosome is the place for protein synthesis and known as the “protein factory of cells.” The ubiquitin-proteasome system has a central role in regulating protein activities as well as cell cycle, gene expression, oxidative stress response, cell survival, cell proliferation, and apoptosis. The p53, previously described as a tumor suppressor, is now considered to be a key component of the mitochondrial apoptosis pathway under cell stress. In response to various stimuli such as hypoxia, DNA damage, and reactive oxygen species, the p53 pathway induces cell death through activation of target genes and transcriptional-independent signal mechanism. It has been reported that silencing of PYCR1 results in activation of p53 pathway and cell cycle arrest in hTERT-immortalized human foreskin fibroblasts. To our knowledge, our work is the first report on the association of PYCR1 mRNA with the p53 pathway, ribosome, and proteasome. However, the prediction of protein expression using RNA-Seq data is far from perfect. Because of limitations in our study design, the correlation between PYCR1 mRNA and PYCR1 protein expression could not be clearly assessed in this report. Further studies on direct mechanisms of PYCR1 in AK are needed.

In conclusion, PYCR1 may be a potential prognostic molecular marker of poor survival in AK. Moreover, the p53 signaling pathway, ribosome, and proteasome may be related to PYCR1 mRNA alteration in AK.

Acknowledgment

The results shown here are based on data generated by the TCGA Research Network.

Author contributions

Conception and design: TY Zhang, XZ Liu, ZF Zuo; Administrative support: XZ Liu, ZF Zuo; Provision of study materials or patients: TY Zhang, Y Liu, WQ Liu, QW Li; Collection and assembly of data: TY Zhang, Y Liu, WQ Liu, QW Li, W Hou, Y Huang, P Lv, L Meng, YH Li, YG Jia; Data analysis and interpretation: TY Zhang, ZF Zuo, XZ Liu; Manuscript writing: All authors; Final approval of manuscript: All authors.

Conceptualization: Tianyi Zhang, Zhongfu Zuo, Xuezheng Liu.

Data curation: Tianyi Zhang, Ying Liu, Wenqiang Liu, Qunwang Li, Wei Hou, Ying Huang, Pan Lv, Lu Meng, Yinhua Li, Yunge Jia.

Formal analysis: Tianyi Zhang, Ying Liu, Wenqiang Liu, Qunwang Li, Wei Hou, Ying Huang, Pan Lv, Lu Meng, Yinhua Li, Yunge Jia.

Funding acquisition: Zhongfu Zuo, Xuezheng Liu.

Investigation: Tianyi Zhang.

Methodology: Tianyi Zhang, Ying Liu, Wenqiang Liu, Qunwang Li.

Project administration: Tianyi Zhang, Zhongfu Zuo, Xuezheng Liu.

Validation: Zhongfu Zuo.

Writing – review & editing: Zhongfu Zuo, Xuezheng Liu.

References

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7–30.
[2] Solarek W, Koper M, Lewicki S, Szczyluk C, Czarnecka AM. Insulin and insulin-like growth factors act as renal cell cancer intratumoral regulators. J Cell Commun Signal 2019;13:381–94.
[3] Zhang H, Wang Z, Xie L, et al. Molecular recognition and in-vitro-targeted inhibition of renal cell carcinoma using a DNA aptamer. Mol Ther Nucleic Acids 2018;12:758–68.
[4] Wu H, Zhang J. Decreased expression of TFAP2B in endometrial cancer predicts poor prognosis: a study based on TCGA data. Gynecol Oncol 2018;149:592–7.
[5] Verbruggen N, Hermans C. Proline accumulation in plants: a review. Amino Acids 2008;35:753–9.
[6] Christensen EM, Patel SM, Korasick DA, et al. Resolving the cofactor-binding site in the proline biosynthetic enzyme human pyrroline-5-carboxylate reductase 1. J Biol Chem 2017;292:7233–43.
[7] Phang JM, Liu W. Proline metabolism and cancer. Front Biosci (Landmark Ed) 2012;17:1835–45.
[8] Phang JM, Liu W, Hancock CN, Fischer JW. Proline metabolism and cancer: emerging links to glutamine and collagen. Curr Opin Clin Nutr Metab Care 2015;18:71–7.
[9] Phang JM. Proline metabolism in cell regulation and cancer biology: recent advances and hypotheses. Antioxid Redox Signal 2019;30:635–49.
[10] Christgen SL, Becker DF. Role of proline in pathogen and host interactions. Antioxid Redox Signal 2019;30:683–709.
[11] Elia I, Broekgaert D, Christen S, et al. Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells. Nat Commun 2017;8:15267.
[12] Kuo ML, Lee MB, Tang M, et al. PYCR1 and PYCR2 interact and collaborate with RRM2B to protect cells from overt oxidative stress. Sci Rep 2016;6:18846.

[13] Ding J, Kuo ML, Su L, et al. Human mitochondrial pyrroline-5-carboxylate reductase 1 promotes invasiveness and impacts survival in breast cancers. Carcinogenesis 2017;38:519–31.

[14] Zeng T, Zhu L, Liao M, et al. Knockdown of PYCR1 inhibits cell proliferation and colony formation via cell cycle arrest and apoptosis in prostate cancer. Med Oncol 2017;34:27.

[15] Cai F, Miao Y, Liu C, et al. Pyrroline-5-carboxylate reductase 1 promotes proliferation and inhibits apoptosis in non-small cell lung cancer. Oncol Lett 2018;15:731–40.

[16] Craze ML, Cheung H, Jewa N, et al. MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer. Br J Cancer 2018;118:258–65.

[17] Olivares O, Mayers JR, Gouirand V, et al. Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions. Nat Commun 2017;8:16031.

[18] Hollinshead KER, Munford H, Eales KL, et al. Oncogenic IDH1 mutations promote enhanced proline synthesis through PYCR1 to support the maintenance of mitochondrial redox homeostasis. Cell Rep 2018;22:3107–14.

[19] Togashi Y, Arai T, Kato H, et al. Frequent amplification of ORAOV1 gene in esophageal squamous cell cancer promotes an aggressive phenotype via proline metabolism and ROS production. Oncotarget 2014;5:2962–73.

[20] Nilsson R, Jain M, Madhusudhan N, et al. Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer. Nat Commun 2014;5:3128.

[21] Ernst T, Hergenhahn M, Kenzelmann M, et al. Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. Am J Pathol 2002;160:2169–80.

[22] Zhang Y, Li Q, Wei S, et al. ZNF143 suppresses cell apoptosis and promotes proliferation in gastric cancer via ROS/p53 axis. Dis Markers 2020;2020:5863178.

[23] Lu ZW, Wen D, Wei WJ, et al. Silencing of PPM1D inhibits cell proliferation and invasion through the p38 MAPK and p53 signaling pathway in papillary thyroid carcinoma. Oncol Rep 2020;43:783–94.

[24] Cen B, Lang JD, Du Y, et al. Prostaglandin E(2) induces miR675-5p to promote colorectal tumor metastasis via modulation of p53 expression. Gastroenterology 2020;158:971–84.e10.

[25] Guo L, Cai C, Zhang K, et al. Kindlin-2 links mechano-environment to proline synthesis and tumor growth. Nat Commun 2019;10:845.

[26] Wang T, Zhang WS, Wang ZX, et al. RAPTOR promotes colorectal cancer proliferation by inducing mTORC1 and upregulating ribosome assembly factor URBI. Cancer Med 2020;9:1529–43.

[27] Narayanan S, Cai CY, Assaraf YG, et al. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. Drug Resist Updat 2020;48:100663.

[28] Wang M, Yang J, Wang C. Shen Shuai II recipe attenuates apoptosis in 5/6 renal ablation/infarction rats by inhibiting p53 and the mitochondrial pathway of apoptosis. Oxid Med Cell Longev 2020;2020:7083575.

[29] Shenoy N, Kessel R, Bhagat TD, et al. Alterations in the ribosomal machinery in cancer and hematologic disorders. J Hematol Oncol 2012;5:32.